Introduction
============

Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) represents 85% of lung tumors.[@b1] As patients are usually diagnosed in advanced stage and cancer metastases are resistant to conventional therapy, the overall survival for patients with lung cancer is still less than 15%, despite great advances in the treatment of cancer in recent years.[@b2]--[@b4]

Several biological markers have been recognized as prognosticators, as well as indicators of potential therapeutic targets for different types of human cancers, including NSCLC. Because of complicated molecular biology, multiple factors including cell growth and cell cycle control, angiogenesis, morphogenesis, apoptosis, and metastatic adhesion have been researched with the aim of creating biological risk assessment and biological staging models for NSCLC.[@b5],[@b6] E-cadherin, as the prime mediator of intercellular adhesion in epithelial cells, is a transmembrane glycoprotein that functions to maintain stable cell-cell contact in epithelial cell types.[@b7] It has an important role in cell adhesion specificities and morphogenesis, and it may have a signaling effect through interaction with the intracellular cytoskeleton where the tyrosine kinase of the *src* family is localized.[@b8],[@b9] Additionally, because cell discohesiveness and detachment are important for tumor invasiveness, decreased expression or loss of E-cadherin may facilitate tumor invasion and metastasis.[@b9],[@b10] Recently, E-cadherin′s downregulation or loss of regulation was a sign of poor prognosis, and showed invasion and metastasis for multiple types of epithelial carcinomas in cases of the breast,[@b11] prostate,[@b12] esophagus,[@b13]--[@b15] stomach,[@b16]--[@b18] colon,[@b19] liver,[@b20],[@b21] pancreas,[@b22] and urinary bladder.[@b23],[@b24] However, the relationship of E-cadherin expression levels to NSCLC patients′ survival and clinicopathological variables remains controversial. Therefore, based on the discordant results obtained by a number of studies, we conducted this meta-analysis to quantify the role of E-cadherin as a prognostic and clinicopathological marker among patients with NSCLC.

Materials and methods
=====================

Literature search
-----------------

A literature search via PubMed, EMBASE and MEDLINE (Ovid) databases was conducted to find articles that evaluated the role of E-cadherin in NSCLC (the last search was updated on 5 December 2013) using the following text and keywords: (i) epithelial cadherin or E-cadherin; (ii) non-small cell lung cancer or NSCLC or lung cancer; (iii) survival analysis or prognostic; (iv) expression; and (v) tissue.

Selection criteria
------------------

There was no restriction on the language in which the articles were published and all eligible studies that examined the association between the expression of E-cadherin and clinicopathological characteristics, progression-free survival (PFS) or overall survival (OS) were included. We carefully searched the titles and abstracts of publications to find those studies that examined the relationship between the expression of E-cadherin and clinicopathological variables and PFS or OS in patients with NSCLC. After the abstracts met these conditions, the full texts were analyzed and included into our meta-analysis according to the following criteria: (i) articles were published as a full paper; (ii) expression levels of E-cadherin were compared to patient′s PFS or OS; (iii) the expression of proteins were evaluated in tumor tissues by immunohistochemistry (IHC) or reverse transcription polymerase chain reaction (RT-PCR) analysis; (iv) sufficient data on hazard ratios (HR) and 95% confidence interval (CI) for survival were provided or could be calculated; (v) patients had NSCLC without receiving neoadjuvant therapy or radio-chemotherapy before complete surgical resection; and (vi) if the same group of patients were used in the analysis more than once, the most complete research was selected.

Data extraction
---------------

Two investigators independently checked all potentially relevant articles and extracted data. In the case of disagreement, a third author would assess these articles. The following information was collected from each study: first author′s name, year of publication, ethnicity, number of patients, laboratory methodology, follow-up time, cut-off value, information about neoadjuvant therapy, smoking status, histological type, lymph node metastasis, clinical stage, and HR with 95% CI.

Statistical analysis
--------------------

The intensity of the relationship between the expression levels of E-cadherin and survival were described as HRs, and the strength of the association between E-cadherin and clinicopathological parameters was expressed as an odds ratio (OR). Positive expression of E-cadherin indicated poor prognosis in patients with NSCLC if HR \> 1 with 95% CI did not overlap 1. In some of the studies, HR and 95% CI were directly obtained using univariate or multivariate survival analysis. Otherwise, HR and 95% CI were calculated by Kaplan--Meier survival curves using Engauge Digitizer Version 4.1 software (<http://digitizer.sourceforge.net/>) and a method previously reported by Parmar *et al*.[@b25] Extracted data were then utilized to reconstruct the HR and its variance (GraphPad Software Inc., La Jolla, CA, USA).

The pooled HR corresponding to 95% CI were used to assess the prognostic value of E-cadherin in patients. Statistical heterogeneity was tested by Cochrane′s Q test (Chi-squared test; Chi^2^) and inconsistency (I^2^).[@b26],[@b27] If there was no obvious heterogeneity, a Mantel-Haenszel fixed-effects model was used to estimate the pooled HR; otherwise, the DerSimonian and Laid random-effects model was used.[@b28] Funnel plot and Begg′s rank correlation method were utilized for assessing the risk of publication bias. STATA 12.0 (STATA Corp., College, TX, USA) was used to perform statistical analysis. A *P*-value of less than 0.05 was considered statistically significant.

Results
=======

Study selection and characteristics
-----------------------------------

Forty-three articles were retrieved from PubMed and 78 articles from EMBASE and MEDLINE (Ovid) (Fig [1](#fig01){ref-type="fig"}). After careful examination of the abstracts, 53 studies that focused on the association between the expression of E-cadherin and survival were included in our full-text review process. After reading the full text, 11 papers were excluded because data were not extractable or did not provide enough survival information, and two papers were excluded because the patients underwent neoadjuvant therapy before complete surgical resection. Finally, 15 studies including 2412 cases were included in the meta-analysis. Among the included studies, 10 papers were in English and five papers were in Chinese.

![Flow chart summarizing the literature search and study selection.](tca0006-0589-f1){#fig01}

The characteristics of the eligible studies are summarized in Table [1](#tbl1){ref-type="table"}. Eleven studies included patients from Asia, three from America, and one from Europe. Expressions of E-cadherin were detected via IHC or RT-PCR. None of these studies analyzed the relationship between E-cadherin expression and PFS in patients with NSCLC; therefore we could only conduct a meta-analysis on the association between the expression level of E-cadherin and OS. According to univariate analysis, two studies directly provided HR with 95% CI, and 13 studies detailed survival curves from which the HR could be calculated. In multivariate analysis, eight studies directly provided the HR with 95% CI, while the remaining seven papers had no data available. ORs were calculated from articles that provided sufficient data comparing the expression of E-cadherin with clinical characteristics (data is not shown).

###### 

Main characteristics and results of eligible studies

  First Author          Year   Ethnicity   Cases   P/N       Method       Follow-up Time   Cutoff-value   Neoadjuvant Therapy   Smoking Status (Yes/No)   Histological Type (SCC/ADC/ Others)   Lymph Node Metastasis (Yes/No)   Stage (I/II/III/IV)   Overall Survival                                           
  --------------------- ------ ----------- ------- --------- ------------ ---------------- -------------- --------------------- ------------------------- ------------------------------------- -------------------------------- --------------------- ------------------ ------- -------------- -------- ------- --------------
  Shinichiro Kase       2000   Japanese    331     193/138   IHC,         60M              \>70%          NA                    NA                        104/227                               125/206                          174/41/104/12         Sur. Curve         0.73    0.51--1.04     NA       NA      NA
  Tang Xiao-jun         2002   Chinese     112     59/53     IHC          60M              NA             NA                    77/35                     44/50/18                              79/33                            17/24/59/12           Sur. Curve         0.21    0.13--0.34     NA       0.965   NA
  Chen Xiao-feng        2002   Chinese     138     57/81     IHC          60M              \>40%          NA                    NA                        57/55/26                              99/39                            26/32/80              Sur. Curve         0.43    0.26--0.70     NA       NA      NA
  George Deeb           2004   American    130     65/53     IHC          57.2M            \>10%          NA                    105/12                    37/81                                 39/79                            97/21(II-IIIa)        HR 95%CI           0.5     0.3--0.8       HR 95%   0.5     0.3--0.9
  Yan Hong              2005   Chinese     129     49/80     IHC          60M              NA             NA                    NA                        56/52/21                              66/63                            44/22/48/15           Sur. Curve         0.69    0.46--0.95     NA       NA      NA
  Shi Rui               2005   Chinese     76      25/51     IHC,         40M              \>60%          NA                    NA                        44/32                                 41/35                            23/11/37/5            Sur. Curve         0.45    0.21--1.3      NA       0.376   NA
  S Al-Saad             2008   Norwegian   335     201/120   IHC          96M              scores\>2      NA                    320/15                    191/95/49                             103/232                          212/91/32             Sur. Curve         0.72    0.54--0.97     HR 95%   1       0.997--2.158
  Yang Liu              2008   Chinese     138     97/41     IHC          120M             NA             NA                    NA                        75/63                                 79/59                            65/58/15(III-IV)      Sur. Curve         0.65    0.43--0.99     HR 95%   0.465   0.252--0.858
  MI Galleges           2009   American    178     32/135    IHC          18Y              NA             24% of patients       130/3/45                  77/64/37                              NA                               90/52/36              Sur. Curve         0.79    0.49--1.3      HR 95%   0.38    0.19--0.77
  Qiang Lin             2010   Chinese     185     90/95     IHC          51M              ≧50%           NA                    93/92                     53/132                                NA                               185(I)                Sur. Curve         1.96    1.07--3.57     HR 95%   1.51    1.03--2.22
  Toshihiro Yamashita   2010   Japanese    117     70/47     IHC          NA               ≧70%           NA                    53/64                     31/86                                 NA                               NA                    HR 95%CI           1.346   0.737--2.460   HR 95%   1.783   0.948--3.353
  WU Shiwu              2012   Chinese     50      24/26     IHC,RT-PCR   41.6 ± 29.5M     scores\>1      No                    NA                        36/14                                 26/24                            8/28/14               Sur. Curve         0.36    0.09--0.94     HR 95%   0.159   0.39--0.649
  Jian Feng             2012   Chinese     103     35/68     IHC,RT-PCR   60M              \>10%          NA                    NA                        46/55/2                               50/53                            50/27/26(III-IV)      Sur. Curve         0.6     0.31--1.14     HR 95%   0.491   0.268--0.900
  Nagaraj S             2012   American    310     161/123   IHC          50M              NA             NA                    243/67                    188/191                               NA                               NA                    Sur. Curve         0.35    0.27--0.46     NA       NA      NA
  Miao Xiao-hui         2012   Chinese     80      27/53     IHC          60M              \>50%          NA                    38/42                     38/42                                 31/49                            62(I-II)/18(III-IV)   Sur. Curve         0.54    0.27--1.07     NA       NA      NA

ADC, adenocarcinoma; HR, hazard ratio; IHC, immunohistochemistry; M, month; NA, not available or not applicable; P/N, positive expression/negative expression; SCC, squamous cell carcinoma; Y, year.

Meta-analysis
-------------

We first evaluated whether E-cadherin expression levels were associated with OS in patients with NSCLC. Of the 15 trials eligible for systematic review, seven articles could not be included in the meta-analysis by multivariate analysis because there was insufficient data to estimate the HR and 95% CI.

Fifteen studies, including 2412 patients, reported the effect of E-cadherin on OS using analyses unadjusted for other factors.[@b2],[@b7],[@b10],[@b29]--[@b40] As shown in Figure [2a](#fig02){ref-type="fig"}, according to univariate analysis, E-cadherin was significantly correlated with favorable OS (HR = 0.55, 95% CI = 0.44--0.69, *P* \< 0.05). The DerSimonian and Laird random effects model was used as significant heterogeneity was observed among the studies (*P* = 0.000, *I*^2^ = 70.1%). Eight studies demonstrated the effect of E-cadherin on OS using analyses adjusted for other factors, including 1119 patients.[@b2],[@b7],[@b10],[@b37],[@b41]--[@b44] As shown in Figure [2b](#fig02){ref-type="fig"}, statistical significance was observed between the expression levels of E-cadherin and OS (HR = 0.68, 95% CI = 0.43--1.08, *P* \< 0.05). The DerSimonian and Laird random-effects model was again used because of significant heterogeneity among the studies (*P* = 0.000, *I*^2^ = 80.3%).

![Forest plots showing the combined relation hazard ratio (HR) from the random effects model for overall survival. (a) Univariate analysis. (b) Multivariate analysis. CI, confidence interval.](tca0006-0589-f2){#fig02}

We performed subgroup analyses to investigate whether there were differences in results with respect to the year of publication, ethnicity, cut-off values and follow-up time in which the study was conducted. Despite the limited number of studies that were eligible for this meta-analysis, in the stratified analysis by ethnicity, decreased risks were found in Chinese (HR = 0.48, 95%CI = 0.36--0.82, *P* = 0.020) and American patients (HR = 0.50, 95% CI = 0.31--0.82, *P* = 0.013). Moreover, subgroup analyses regarding the year of publication revealed that articles published in 2012 showed a favorable prognostic value for survival in NSCLC (HR = 0.40, 95% CI = 0.31--0.52, *P* = 0.363). However, statistically significant results from other factors were unavailable (Supporting Information [Figure S1A](#sd1){ref-type="supplementary-material"} and [B](#sd1){ref-type="supplementary-material"}).

Publication bias was determined using the Begg′s test (Supporting Information [Figure S1C](#sd1){ref-type="supplementary-material"}). No publication biases were found in the 15 OS studies using univariate analysis (*P* = 0.889) or in the eight OS studies using multivariate analysis (*P* = 0.061). Sensitivity analysis was performed to investigate the effect of each study on the overall meta-analysis by omitting one study at a time, and the omission of any study made no significant difference, demonstrating that our results were statistically reliable.

In order to gain further insight into the role of E-cadherin as biological marker, we investigated the relationship between E-cadherin expression and clinicopathological variables (Table [2](#tbl2){ref-type="table"}). Although there were a limited number of studies, a random effects model revealed an association between the expression of E-cadherin and the presence of lymph node metastasis (Fig [3](#fig03){ref-type="fig"}). The number of patients with positive lymph node metastasis was lower in the group of E-cadherin positive expression (OR = 0.46, 95% CI = 0.08--0.79, *P* = 0.001).

###### 

Meta-analysis assessing the association between E-cadherin expression and clinicopathological variables

  Clinicalpathological Variable         No. of Studies   Pooled Data(Random)   Test for Heterogeneity                                        
  ------------------------------------- ---------------- --------------------- ------------------------ ------------ ------- ------- ------- --------
  Gender(male/female)                   5                508                   0.89                     0.50--1.29   0.000   1.44    0.837   0.000
  Age(\<60/ ≥ 60)                       3                206                   0.95                     0.30--1.60   0.004   0.04    0.980   0.000
  Histological Type(SCC/ADC)            8                1106                  0.68                     0.36--1.00   0.087   14.63   0.041   52.200
  Differentiation(well-moderate/poor)   4                555                   1.71                     0.91--2.52   0.000   0.79    0.851   0.000
  Lymph Node Metastasis                 5                744                   0.46                     0.08--0.79   0.025   20.78   0.001   75.850
  TNM Stage (I-II/III-IV)               4                555                   1.23                     0.59--1.87   0.000   1.57    0.666   0.000

ADC, adenocarcinoma; No., number; SCC, squamous cell carcinoma.

![Forest plots reflects the combined odds ratio (OR) with 95% confidence interval (CI) for the association between E-cadherin expression and lymph node metastasis.](tca0006-0589-f3){#fig03}

Discussion
==========

Immortalization and invasiveness are important characteristics of cancer tissues, and postoperative recurrence and metastasis are the principal causes for treatment failure and death in patients with NSCLC. Based on these reasons, identifying the specific molecular markers to distinguish resectable NSCLC patients with a high risk of recurrence is crucial to improving therapeutic outcome. Therefore, several biological effectors related to cell growth, differentiation, and adhesions have been studied in individuals who have developed NSCLC. In earlier studies, various kinds of genetic alterations have been identified as prognostic factors, such as human epidermal growth factor receptor 2 in breast carcinoma and the epidermal growth factor receptor gene in NSCLC.[@b45] However, most other clinically useful molecular markers with a prognostic value and predictive value of therapeutic response failed to demonstrate usefulness in subsequent investigations.

E-cadherin is a cell-cell adhesion transmembrane molecule that connects epithelial cells via homotypic calcium-dependent interactions. It also plays an important role in cellular adhesion activity and as an invasion or metastasis suppressor by signal transduction.[@b7] In recent years, some studies have shown that E-cadherin expression was highly downregulated in a variety of cancers, including hepatocellular cancer, retinoblastoma, endometrial carcinoma and gastric cancer,[@b41]--[@b44],[@b46] which correlated with malignancy, metastasis, and clinical stage. Moreover, several studies reported that a low expression of E-cadherin in NSCLC was associated with more aggressive behavior of tumor epithelial cells and a poor prognosis.[@b2],[@b47] Lee *et al*., however, studied 115 patients with NSCLC for E-cadherin expression using IHC, and found that E-cadherin expression had no prognostic value in multivariate analysis, although it was associated with differentiation, invasiveness, and advanced stage.[@b48] Kase *et al*. assessed the expression of E-cadherin in 331 cases of NSCLC using IHC, and concluded that there was no independent predictive value of E-cadherin as a disease prognosticator.[@b34] Thus, because of contrasting results of the prognostic implication of E-cadherin in NSCLC, we undertook a meta-analysis to determine whether E-cadherin could serve as a prognostic marker for patients with NSCLC.

Our meta-analysis focused on the relationship between E-cadherin expression and OS or clinicopathological parameters in resected NSCLC. We also collected information on the relationship between the E-cadherin expression and PFS, but could not conduct a meta-analysis because of insufficient data. Although the results of six studies[@b7],[@b29],[@b34],[@b35],[@b38],[@b40] which reported the impact of E-cadherin expression on OS had no statistical significance compared with the other nine studies[@b2],[@b10],[@b32],[@b33],[@b36],[@b37],[@b39] in the meta-analysis, our meta-analysis with accumulated data suggested that an overexpression of E-cadherin was associated with longer OS and predicted favorable prognosis in patients with NSCLC. The pooled HR for OS was 0.55 (95% CI: 0.44-0.69) by univariate analysis and 0.68 (95% CI: 0.43--1.08) by multivariate analysis. Furthermore, a small number of studies investigated the association between E-cadherin expression and lymph node metastasis or histological type, and interestingly found that the expression of E-cadherin correlated with the existence of lymph node metastasis (OR: 0.37, 95% CI: 0.05--0.69).

Our meta-analysis was based on published data and was performed using univariate analysis followed by further multivariate analysis, which, to our knowledge is the first evaluation of the effect of E-cadherin on OS for NSCLC. However, some limitations exist in our study. We did not include unpublished studies and abstracts in our meta-analysis because the required data was not available. Additionally, the risks calculated in our meta-analysis might be overestimated as a result of publication and reporting bias. Positive results tend to be accepted by journals, whereas negative results are often rejected or not submitted. Another potential source of bias is related to the method used to extrapolate the HR. HR was extracted from the data included in the article directly or calculated from survival curves. The method of extrapolating HR from survival curves did not completely eliminate inaccuracy in the extracted survival rates. Furthermore, we included studies that used IHC. Prognostic markers based on IHC can provide inconsistent or contradictory results, because of the use of different antibodies and processing methods, as well as different scoring and categorization systems.[@b34] It would be desirable to have IHC findings reported carefully and in detail. Moreover, different therapy strategies used for patients after surgery in these studies had different impacts on OS, and should be taken into consideration. Unfortunately, only one of these studies described the therapy strategy after the patients had been diagnosed with lung cancer. Therefore, more meticulous research should be conducted. We performed stratified analysis because of the limited number of studies; however, the results had no statistical significance. Nevertheless, no publication bias was detected using the Begg′s test (*P* \> 0.05), indicating that the statistics obtained approximated the actual results. Sensitivity analysis was also conducted to investigate the influence of a single study on the overall meta-analysis by omitting one study at a time, and the omission of any study made no significant difference, suggesting that our results were statistically reliable.

Conclusion
==========

In summary, on univariate analysis the over-expression of E-cadherin was associated with favorable OS in patients with NSCLC and it might act as an inhibition factor of lymph node metastasis. Undoubtedly, these results should be confirmed by more prospective and randomized clinical studies; however, they provide new insights that support E-cadherin as a potential prognostic biomarker and biological target for anticancer therapies in NSCLC.
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**Figure S1** A. Stratified analysis by ethnicity. B. Stratified analysis by year of publication. C. Funnel blots of meta-analysis.
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